Year None202120202019201820172016 Date Latest Press Release October 1, 2021 Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) September 21, 2021 Eiger BioPharmaceuticals Appoints Erik Atkisson as General Counsel and Chief Compliance Officer September 20, 2021 Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients September 1, 2021 Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor Conferences August 5, 2021 Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update August 5, 2021 Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism August 3, 2021 Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences July 22, 2021 Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5 July 7, 2021 Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference July 6, 2021 Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
